Neurology · Anticonvulsant
The FDA's approval of Ascent Pharmaceuticals' gabapentin under ANDA214956 signifies a competitive shift in the generic neurology market. This could lead to pricing pressures and market share changes among existing competitors, necessitating strategic adjustments.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/6/2026, 12:34:40 AM
Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Ascent Pharmaceuticals' gabapentin under ANDA214956 signifies a competitive shift in the generic neurology market. This could lead to pricing pressures and market share changes among existing competitors, necessitating strategic adjustments. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).
Portfolio teams should assess the competitive landscape for gabapentin and consider potential pricing strategies and market entry timing. The strongest clinical anchor is Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 5 regulatory and 3 competitive items passed relevance filtering for Ascent Pharmaceuticals.
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement. This approval may enhance Ascent Pharmaceuticals' market presence in the generic gabapentin segment, impacting competitors in the neurology space.
Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (gabapentin); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval indicates a successful navigation of the regulatory landscape, but ongoing monitoring of compliance and potential challenges from branded competitors is essential.
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin); Regulatory pathway relevance (nda)
FDA document
View sourceClass 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
MHRAhigh relevance
Entity match (gabapentin)
FDA document
View sourceLentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceAutomated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNatural History of Spinocerebellar Ataxia Type 7 (SCA7)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceDZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Ascent Pharmaceuticals' gabapentin under ANDA214956 signifies a competitive shift in the generic neurology market. This could lead to pricing pressures and market share changes among existing competitors, necessitating strategic adjustments.
Ascent's entry into the gabapentin market may dilute the market share of current players, impacting revenue streams and competitive positioning in the neurology segment.
The approval indicates a successful navigation of the regulatory landscape, but ongoing monitoring of compliance and potential challenges from branded competitors is essential.
Monitor for market launch dates and any potential challenges from branded competitors.
Track for follow-up milestones; no immediate action required.